Archived weekly brief

Weekly NADAC Price Changes

A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.

Week of November 18, 2026

Compared with November 11, 2026

Weekly NADAC pricing brief
Published NDCs
30,211
Price increases
15,052
Price decreases
13,763
Unchanged prices
1,296

NADAC Update: Biologic Price Relief Offsets Broad-Based Generic Increases

The November 18, 2026 NADAC release reflects a near-balanced market with 15,052 price increases against 13,763 decreases across 30,111 comparable NDCs, though dollar-weighted impact skews toward relief in high-cost specialty categories. The Interleukin-23 Antagonist class posted the largest aggregate price pressure at -$1.5M, driven primarily by risankizumab-rzaa, while AbbVie Inc. recorded the largest manufacturer-level decline (-$837.4K) across 64 products. Partially offsetting this, Risperidone saw a +3.5% average increase across 114 NDCs, contributing $677.1K in added cost, and broad-based Corticosteroid movement (1,102 drugs) remained modest despite its scale.

Key takeaways

  • Price activity was nearly even (15,052 increases vs. 13,763 decreases), indicating no dominant market-wide directional trend this week.
  • High-impact declines were concentrated in specialty and GLP-1 categories: Interleukin-23 Antagonist (-$1.5M), Opioid Antagonist (-$1.1M), and GLP-1 Receptor Agonist (-$922.3K) led dollar-weighted relief.
  • Generic breadth drove notable cost pressure, with Risperidone (+3.5%, 114 NDCs) and broad Corticosteroid movement (1,102 drugs) signaling sustained upward pressure outside specialty tiers.

What to watch

Naloxone Hydrochloride Pricing Shift

A -6.8% average move across 20 NDCs produced a -$986.8K impact, with Padagis Israel Pharmaceuticals products (including a -7.4% NDC-level decline) contributing significantly; payers should monitor formulary cost basis for opioid antagonists.

GLP-1 and Liraglutide Volatility

Liraglutide fell -8.0% across 12 NDCs (-$641.6K), part of a broader -$922.3K decline in the GLP-1 Receptor Agonist class; procurement teams should reassess contract pricing assumptions given continued downward momentum.

Interleukin-23 Antagonist Concentration Risk

Despite covering only 4 drugs, this class drove the largest weighted impact (-$1.5M), led by risankizumab-rzaa (-$739.6K across 2 NDCs) and AbbVie's broader -$837.4K swing; limited breadth means pricing shifts here can materially affect specialty drug budgets.

Largest cost pressure

$668.0KUp

Largest absolute weekly price increase in the current release

Largest relief

$642.7KDown

Largest absolute weekly price decline in the current release

Most pressured class

Highest weighted movement this week

Largest manufacturer swing

Largest aggregate movement across tracked NDCs

Top 10 NDCs by weekly price movement

Up to 10 changed products are shown. Each edition preserves its published price comparison.

Notes and methodology

How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.

Publication comparison

Prices are compared between the two CMS publication dates shown above, using weekly history snapshots. An unchanged effective date does not mean a publication is missing. NDCs absent from the previous publication are excluded from change calculations; missing prices are not counted as unchanged.

Top mover ranking

The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available. The current release had 28,815 NDCs with a measurable publication-to-publication change.

Segment summaries

Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when the volume table is available.

Headline cards and archive stability

In editions with headline cards, most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.

More archived editions

Each edition is permanently archived under its release date.

Full archive

Explore the broader trend ecosystem